|
AU2018334152A1
|
|
CXCR-2 inhibitors for treating disorders
|
|
US2018221312A1
|
|
Cxcr-2 inhibitors for treating disorders
|
|
MX2018010946A
|
|
Cxcr-2 inhibitors for treating crystal arthropathy disorders.
|
|
WO2017147270A1
|
|
Atropisomers of triazole derivative
|
|
AU2016368622A1
|
|
Pharmaceutical composition comprising a potent inhibitor of URAT1
|
|
US2017183333A1
|
|
Derivatives of n-(arylamino) sulfonamides as inhibitors of mek
|
|
US2016271122A1
|
|
Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
|
|
US2014128338A1
|
|
Compounds, compositions and methods of using same for modulating uric acid levels
|
|
US2015252010A1
|
|
Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
|
|
AU2013202822A1
|
|
Thioacetate compounds, compositions and methods of use
|
|
ZA201302565B
|
|
Methods for treating hyperuricemia and related diseases
|
|
BR112014010495A2
|
|
3,4-disubstituted pyridine compound, methods of use and compositions comprising the same
|
|
AU2012209027A1
|
|
Compounds, compositions and methods of using same for modulating uric acid levels
|
|
AU2012203082A1
|
|
Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
|
|
CN103702986A
|
|
Hypertension and hyperuricemia
|
|
AU2011352129A1
|
|
Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
|
|
CA2802692A1
|
|
Phenylthioacetate compounds useful as uricosuric agents
|
|
WO2011159732A1
|
|
Treatment of gout and hyperuricemia
|
|
AR081930A1
|
|
THIOACETATE COMPOUNDS
|
|
EP2560642A2
|
|
Treatment of gout
|
